2020/November - Latest news from KCE Trials
Open calls for proposals – possibilities of funding
Two calls for proposals are currently open: the BeNeFIT-2 call (a collaboration with ZonMw in the Netherlands) and the Covid-19 fast track rolling call for clinical studies.
The dynamic dashboard has had a make-over
More information has been added to the dashboard, check it out via https://trials.kce.be/dashboard/
Covid studies are recruiting fast and some results will be available soon
KCE Trials has already funded 4 RCTs on covid-19 treatment, for a total budget of € 7.5M. More than 800 patients have been recruited across these studies to date. Hôpital Erasme, CHC MontLégia, CHR de la Citadelle, CHU St- Pierre and CHU de Liège are currently the top 5 recruiters.

Progress in funded studies
We are happy to announce the following important milestones have been reached:
- FPI (First Patient In) in Belgium for the ALL Together study, a trial for children and young adults with acute lymphoblastic leukaemia (ALL). This is an international initiative led by the Karolinska University Hospital (Sweden). UZ Gent is the Belgian Coordinating Centre with Prof Veerle Mondelaers the Lead-Investigator in Belgium: the study will recruit 510 participants in departments of pediatric hemato-oncology of 8 different university hospitals and is also supported by The Belgian Society of Paediatric Haematology and Oncology (BSPHO).
- FPI (First Patient In) in Belgium for the BeNeBio study. This study is part of the BeNeFit call and is a collaboration between Radboud UMC and UZ Gent. Prof Jo Lambert is the Coordinating Investigator for Belgium. It studies the effect of dose reduction in psoriasis patients who are treated with a new generation biologics (IL17 and IL23 inhibitors).
- Full results are published for the ELMO study, led by Dr Nicolas Delvaux from KU Leuven, in the Implementation Science Journal: “Clinical decision support improves the appropriateness of laboratory test ordering in primary care without increasing diagnostic error: the ELMO cluster randomized trial”.